Companies must understand how today’s new pharmaceutical landscape is causing a dramatic shift in how we plan for and execute drug development and manufacturing.
Bypassing conventional trial-and-error methods for solubility challenges and excipient selection can eliminate unnecessary testing, improve the efficacy of your formulation, and increase your overall speed-to-market.
Currently, about 70 percent of new molecular entities exhibit poor solubility in water and require some form of enhancement in order to achieve sufficient bioavailability. However, the sheer number of potential strategies for improving the solubility of a compound can overwhelm many developers, leaving them unsure how to choose a path forward.
Finding a balance between a complex API, its formulation, and its synthesis requires equipment, knowledge, and processes more extensive than those typically required for traditional drug development.
This website uses cookies to ensure you get the best experience on our website. Learn more
